Hansa Biopharma announces participation in Fall conferences and an updated financial calendar
Hansa Biopharma has been invited to participate in several leading global healthcare conferences during the Fall 2020.
Hansa Biopharma will host a Capital Markets Day event on October 29, 2020 in Copenhagen as a combined virtual/physical setup.
Aug 31, 2020, 02:12 ET
LUND, Sweden, Aug. 31, 2020 /PRNewswire/ -- Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced that the Company's management team will present at the following upcoming investor conferences in September:
- Pareto Securities Health Care Conference on Thursday September 3, 2020, at 15:30 CET
- Citibank's Annual BioPharma Virtual Conference on Wednesday September 9, 2020
- H.C.Wainwrigth Healthcare Conference on Tuesday September 15, 2020
- Bank of America Merill Lynch Healthcare Conference on Wednesday September 16, 2020
- MorganStanley Global Healthcare Conference on Friday September 18, 2020 at 8:00am EST/14:00 CET
- ABG Small & Midcap Seminar, Copenhagen on Wednesday September 23, 2020 at 13:30 CET
A link to the presentations and webcasts will be available on the Events & Presentations page of the Company's website at http://www.hansabiopharma.com.
Calendar
Aug 31,2020 Kempen Road Show, Tel Aviv/Paris/Benelux (virtual)
Sep 3, 2020 Pareto Healthcare Conference, Stockholm (virtual)
Sep 9, 2020 Citibank's Annual BioPharma Virtual Conference, Boston (virtual)
Sep 15, 2020 H.C. Wainwright Healthcare Conference, NYC (virtual)
Sep 16, 2020 Bank of America Merill Lynch Healthcare Conf., London (virtual)
Sep 18, 2020 MorganStanley Global Healthcare Conference, NYC (virtual)
Sep 23, 2020 ABG Small & Mid Cap Seminar, Copenhagen and virtual
Oct 22, 2020 Interim Report Jan-Sep 2020
Oct 29, 2020 Hansa Biopharma Capital Markets Day, Copenhagen and virtual
Nov 17, 2020 Bryan Garnier Healthcare Conference, Paris
Nov 18, 2020 Jefferies Healthcare Conference, London
Nov 25, 2020 Ökonomisk Ugebrev Life Science Conference, Copenhagen
Feb 2, 2021 Interim report for Jan - Dec 2020
April 8, 2021 Annual Report 2020
April 22, 2021 Interim report for Jan - Mar 2021
July 15, 2021 Interim report for Jan - Jun 2021
Oct 21, 2021 Interim report for Jan - Sep 2021
CONTACT:
For further information, please contact:
Klaus Sindahl, Head of Investor Relations
Hansa Biopharma
Mobile: +46 (0) 709-298 269
E-mail: [email protected]
Katja Margell
Head of Corporate Communications
Hansa Biopharma
Mobile: +46 (0) 768-198 326
E-mail: [email protected]
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
SOURCE Hansa Biopharma AB
